Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Hemi-Gland Cryoablation for Prostate Cancer at UCLA

NCT: NCT03503643 · COMPLETED

NCT IDNCT03503643
StatusCOMPLETED
Start Date2017-09-14
Completion2025-08-30

Brief Summary

This is a prospective data collection of men who are electing to undergo prostate hemi-gland cryoablation. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using hemi-gland cryoablation. UCLA patients undergoing hemi-gland cryoablation are a unique cohort compared to prior research because all patients at UCLA have had a pre-treatment multi-parametric MRI and Ultrasound fusion targeted biopsy; they will be followed in a similar fashion. This results in more precise assessment of a target region of cancer for ablation which may, in turn, result in improved clinical outcomes.

Frequently Asked Questions

What is Hemi-Gland Cryoablation for Prostate Cancer at UCLA?

Hemi-Gland Cryoablation for Prostate Cancer at UCLA is a clinical trial registered under NCT03503643. Current status: COMPLETED.

What is the status of NCT03503643?

The current status of NCT03503643 (Hemi-Gland Cryoablation for Prostate Cancer at UCLA) is: COMPLETED.

When did Hemi-Gland Cryoablation for Prostate Cancer at UCLA start?

Hemi-Gland Cryoablation for Prostate Cancer at UCLA started on 2017-09-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.